Corsair Gaming Inc vs Cassava Sciences Inc — how do they compare? Corsair Gaming Inc trades at $13.63 (market cap $1.42B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Corsair Gaming Inc is far larger — about 36× Cassava Sciences Inc's market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Cassava Sciences Inc for 37 Days on average.
| CRSR | FLNA | |
|---|---|---|
Market Cap | $1.42B | $39.40M |
Volume | 1,160,938 | 759,018 |
Sector | Technology | Health |
52-Week High | $14.35 | $4.64 |
52-Week Low | $4.58 | $0.68 |
Typical Hold Time | 25 Days | 37 Days |
Enterprise Value | $1.41B | -$43.28M |
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.09, down 3.68% today but showing strong earnings momentum with three consecutive quarterly beats. The stock maintains a bullish technical signal with current price near pivot point support at $13. Recent Q2 2026 results exceeded expectations with EPS of $0.23 versus $0.07 estimate, driving positive sentiment from institutional investors including Canada Pension Plan's new position. The company continues product innovation with VOXARA microphone launch and strategic acquisitions like Trak Racer assets.
While valuation appears elevated with P/E of 42.23, improving profitability trends and raised 2026 guidance support upside potential. Key risks include competitive gaming peripherals market and inconsistent cash flow generation. Analyst consensus shows mixed sentiment with 36% buy ratings but average price target of $12.40 suggests limited near-term upside from current levels.
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →